| Drug Type Universal CAR-T | 
| Synonyms LMY 232, LMY-232 | 
| Target- | 
| Action- | 
| Mechanism Cell replacements, Immunologic cytotoxicity | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United States  | - | |
| Solid tumor | Preclinical | United States  | - | |
| Esophageal Carcinoma | Discovery | United States  | 01 Jun 2025 | |
| Renal Cell Carcinoma | Discovery | United States  | 01 Jun 2025 | 





